This report provides the strategists, marketers and senior management with the critical information they need to assess the demand for anti-asthmatics and COPD drugs market which play a critical role in the treatment of patients with Covid 19.

The global anti-asthmatics and COPD drugs market reached a value of nearly $40,162.1 million in 2019, having grown at a compound annual growth rate (CAGR) of 4.4% since 2015. The global anti-asthmatics and COPD drugs market is expected to grow from $40,162.1 million in 2019 to about $49,384.3 million in 2020 due to an increase in demand for the use of anti-asthmatics and COPD drugs in the treatment of Covid-19 patients.

The global anti-asthmatics and COPD drugs market is expected to grow at a CAGR of 4.1% to nearly $47,176.2 million by 2023. Also, the market is expected to grow to $51,164.1 million in 2025 at a CAGR of 4.1% and to $63,579.9 million in 2030 at a CAGR of 4.4%.

Reasons to Purchase

Outperform competitors using accurate up to date demand-side dynamics information.

Understand how the market is experiencing rapid growth due to the coronavirus and how it is likely to stabilize as the impact of the virus abates.

Identify growth segments for investment.

Facilitate decision making on the basis of historic and forecast data and the drivers and restraints on the market.

Create regional and country strategies on the basis of local data and analysis.

Stay abreast of the latest customer and market research findings

Benchmark performance against key competitors.

Develop strategies based on likely future developments.

Utilize the relationships between key data sets for superior strategizing.

This report describes and evaluates the global anti-asthmatics and COPD drugs market. It covers two five-year periods, one three-year period, and one six-year period including, 2015 to 2019, termed the historic period, and 2019 to 2023 forecast period, 2023-2025 forecast period and 2025 -2030 the forecast period.

Growth in the historic period resulted from increased prevalence of respiratory diseases, increasing incidence of tobacco smoking, global warming, geriatric population, new methods for drug discovery, and rise in healthcare expenditure. Factors that negatively affected growth in the historic period were expiration of patents and political uncertainties.

Going forward, the increased popularity of e-cigarettes/vaping, rising obesity levels, technology, large pool of undiagnosed population, use of anti-asthmatics and COPD drugs to treat COVID-19 patients, and increasing consumption of fats are expected to drive the market. Factors that could hinder the growth of the anti-asthmatics and COPD drugs market in the future include side effects associated with respiratory drugs, reduction in free trade, and stringent regulations.